Diabetes Mellitus as One of the Risk Factors Contribute to Carcinogenesis
Diabetes mellitus (DM) and cancer are both global diseases whose numbers continue to grow. Higher risk of developing cancer in diabetic patients, especially in liver, endometrial, pancreatic, kidney, colorectal, bladder, and breast cancer, was already shown in several previous studies. This review will explain the possible DM pathogenesis that plays a role in carcinogenesis using the simple but thorough concept of insulin resistance, hyperglycemia, and chronic inflammation. By knowing the link, it is hoped that this review can be useful in developing cancer prevention plans for those with diabetes.
Cho NH, Shaw JE, Karuranga S, Huang Y, Rocha-Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res and Clin Pract. 2018;138:271–81.
World Health Organization. Diabetes. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes [Accessed 4 December 2019].
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.
Giovannucci E, Harlan DM, Archer MC. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674-85.
Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo M, Ventura V, et al. Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;1:1-12.
Vázquez-Jiménez JG, Roura-Guiberna A, Jiménez-Mena LR, Olivares-Reyes JA. Role of free fatty acids on insulin resistance. Gac Med Mex. 2017;153:773-83.
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Luu HH. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development
of cancer drug resistance. Genes Dis. 2015;2(1):13–25.
Cifarelli V, Hursting SD. Obesity, diabetes, and cancer: A mechanistic perspective. Int J Diabetol Vasc Dis Res. 2015;4:1-14.
González N, Prieto I, Del Puerto-Nevado L. 2017 Update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget. 2017;8(11):18456-85.
Calle E, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.
Duan WX, Shen X, Lei JJ, Xu QH, Yu YT, Li R et al. Hyperglycemia, a neglected factor during cancer progression. BioMed Res Int. 2014;2014:1-10.
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27–47.
Alisson-Silva F, Freire-de-Lima L, Donadio JL, Lucena MC, Penha L, Sa-Diniz JN, et al. Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells. PLoS ONE. 2013;8:e60471.
Chocarro-Calvo A, García-Martínez JM, Ardila-González S, De la Vieja A, García-Jiménez C. Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer. Mol Cell. 2013;49:474–486.
White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219–32.
Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87:504–8.
Del-Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med. 2011;21:264–75.
Li Q, Engelhardt JF. Interleukin-1 beta induction of NF-kappaB is partially regulated by H2O2-mediated activation of NF-kappaB-inducing kinase. J Biol Chem. 2006;281(3):1495–505.
Albensi BC. What is nuclear factor kappa B (NF-κB) doing in and to the mitochondrion? Front Cell Dev Biol. 2019;7:154.
Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C, Ghirlanda G. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010;7:15–25.
Ben Sahra, I. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366–72.
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77.
Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;41:1-6.
Mogavero A, Maiorana MV, Zanutto S, et al. Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. Sci Rep. 2017;7(1):1-9.
Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, et al. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Oncotarget. 2017;8:16017-26.
Cho O, Oh YT, Chun M, Noh OK, Heo J. Influence of insulin therapy for type 2 diabetes mellitus on cancer incidence. J Clin Oncol 2017;35:15_suppl, e13036-e13036.
Seabloom DE, Galbraith AR, Haynes AM, Antonides JD, Wuertz BR, Miller WA. Fized-dose combinations of Pioglitazone and Metformin for lung cancer prevention. Cancer Prev Res (Phila). 2017;10(2):116-23.
Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. The Lancet Oncology. 2016;17:475-83.
Ballinger T, Marino N, German R, True J, Lu X, Cao S, et al. Prospective, placebo-controlled, randomized study of metformin for breast cancer prevention in overweight/ obese women. Cancer Res. 2020;80: P1-13-03.
American Diabetes Association. Diabetes Care. 2019;42 Supplement 1:S46–S60
Dahl WJ, Stewart ML. Position of the academy of nutrition and dietetics: Health implications of dietary fiber. J Acad Nutr Diet. 2015;115(11):1861-70.
Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016. 39(11):2065–79.
Riddell MC, Milliken J. Preventing exercise- induced hypoglycemia in type 1 diabetes using real-time continuous glucose monitoring and a new carbohydrate intake algorithm: an obser- vational field study. Diabetes Technol Ther. 2011;13:819–825
Article MetricsAbstract view : 85 times
PDF - 30 times
- There are currently no refbacks.
Copyright (c) 2020 Indonesian Journal of Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.